4hle
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | [[ | + | ==Compound 21 (1-alkyl-substituted 1,2,4-triazoles)== |
| + | <StructureSection load='4hle' size='340' side='right' caption='[[4hle]], [[Resolution|resolution]] 2.78Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4hle]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4HLE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4HLE FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=17V:2-[1-(PROPAN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]-4,5-DIHYDROTHIENO[3,2-D][1]BENZOXEPINE-8-CARBOXAMIDE'>17V</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">p110 gamma, PIK3CG ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4hle FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4hle OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4hle RCSB], [http://www.ebi.ac.uk/pdbsum/4hle PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Substructural class effects surrounding replacement of a 'cis'N-methyl aniline amide within potent and selective thienobenzoxepin PI3-kinase inhibitors are disclosed. While a simple aryl to alkyl switch was not tolerated due to differences in preferred amide conformation, heterocyclic amide isosteres with maintained aryl substitution improved potency and metabolic stability at the cost of physical properties. These gains in potency allowed lipophilic deconstruction of the arene to simple branched alkyl substituents. As such, overall lipophilicity-neutral, MW decreases were realized relative to the aniline amide series. The improved properties for lead compound 21 resulted in high permeability, solubility and bioavailability. | ||
| - | + | Cis-Amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.,Staben ST, Blaquiere N, Tsui V, Kolesnikov A, Do S, Bradley EK, Dotson J, Goldsmith R, Heffron TP, Lesnick J, Lewis C, Murray J, Nonomiya J, Olivero AG, Pang J, Rouge L, Salphati L, Wei B, Wiesmann C, Wu P Bioorg Med Chem Lett. 2012 Nov 5. pii: S0960-894X(12)01423-0. doi:, 10.1016/j.bmcl.2012.10.121. PMID:23265894<ref>PMID:23265894</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| + | </div> | ||
| - | + | ==See Also== | |
| - | + | *[[Phosphoinositide 3-Kinases|Phosphoinositide 3-Kinases]] | |
| - | == | + | == References == |
| - | [[ | + | <references/> |
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category: Murray, J M | + | [[Category: Murray, J M]] |
| - | [[Category: Rouge, L | + | [[Category: Rouge, L]] |
| - | [[Category: Wu, P | + | [[Category: Wu, P]] |
[[Category: Kinase]] | [[Category: Kinase]] | ||
[[Category: Lipid kinase]] | [[Category: Lipid kinase]] | ||
[[Category: Transferase-transferase inhibitor complex]] | [[Category: Transferase-transferase inhibitor complex]] | ||
Revision as of 09:18, 10 December 2014
Compound 21 (1-alkyl-substituted 1,2,4-triazoles)
| |||||||||||
